Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftriaxone + rifampin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination antibiotic therapy consisting of ceftriaxone, a third-generation cephalosporin, and rifampin, an antimicrobial agent. Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while rifampin inhibits bacterial RNA synthesis by binding to the beta-subunit of DNA-dependent RNA polymerase. This combination is primarily used for treating bacterial meningitis, particularly pneumococcal meningitis, where it has been shown to decrease lipoteichoic acid concentrations in cerebrospinal fluid and reduce neuronal damage.
02
Targets
Beyond the preview
Go deeper on ceftriaxone + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftriaxone + rifampin.